their blood products utilization rates by more than 20%. Programs that optimize use of supplemental iron, whether in conjunction with the prescription of ESAs or alone, may have the potential to bring clinical benefit and greater efficiencies in the
© 2019-2023 National Comprehensive Cancer Network